Anthony Altig - Assembly Biosciences Insider

Assembly Biosciences Inc -- USA Stock  

USD 30.38  0.86  2.75%

Independent Director

Mr. Anthony E. Altig is Independent Director of ASSEMBLY BIOSCIENCES, Inc., since January 2012. Since 2008, Mr. Altig was the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables. From 2004 to 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporationrationration, a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company. In addition, Mr. Altig serves as a director and chairman of the audit committee for TearLab Corporationrationration, a publicly traded eyecare technology company, and served as a director of Optimer Pharmaceuticals, Inc., a pharmaceutical company, which was a public company until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013.
Age: 60  Director Since 2012      
646 706-5208

Management Efficiency

The company has return on total asset (ROA) of (26.59) % which means that it has lost $26.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.48) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives


Trent DavisVBI Vaccines Inc
Scott RequadtVBI Vaccines Inc
Robert TothDel Mar Pharmaceuticals Inc
Arlene MorrisDimension Therapeutics Inc
Ruth AlonVascular Biogenics Ltd
Robert RosenNantKwest Inc
Dennis BrownDel Mar Pharmaceuticals Inc
Steven GilmanVericel Corporation
Jecheskiel GonczarowskiVascular Biogenics Ltd
Michael DybbsDimension Therapeutics Inc
Adam LogalVBI Vaccines Inc
Ruth ArnonVascular Biogenics Ltd
John BellDel Mar Pharmaceuticals Inc
George MigauskyDimension Therapeutics Inc
Alan RubinoVericel Corporation
Lynda CranstonDel Mar Pharmaceuticals Inc
John PottsNantKwest Inc
Alan ColowickDimension Therapeutics Inc
Dmitry GenkinVBI Vaccines Inc
Dan GelvanVascular Biogenics Ltd
Henry JiNantKwest Inc

Entity Summary

Assembly Biosciences, Inc., a biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and to restore health to a dysbiotic microbiome in the United States. Assembly Biosciences Inc (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 65 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Idea Optimizer Now

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Hide  View All  Next  Launch Idea Optimizer
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Assembly Biosciences Inc to your portfolio

Top Management

Assembly Biosciences Inc Leadership Team
Adam Zlotnick, Founder
Uri Lopatin, President, Ph.D
Myron Holubiak, Director
Lee Arnold, Executive, Ph.D
Anthony Altig, Director
Richard Colonno, Executive
William Ringo, Chairman, MBA
Richard DiMarchi, Director, Ph.D
Miguel Barbosa, Executive, Ph.D
Mark Auerbach, Director
Derek Small, CEO
Alan Lewis, Director, Ph.D
David Barrett, COO

Stock Performance

Assembly Biosciences Performance Indicators